« previous next »
Pages: [1]

Author Topic: (Abst.) Efficacy and safety of ozanimod in MS  (Read 231 times)

0 Members and 2 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9841
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 SUNBEAM trial
« on: September 08, 2019, 04:17:59 pm »
Abstract of an article in The Lancet (September 3, 2019) about a different trial  (see previous post) involving ozanimod and interferon beta-1a--"Safety and efficacy of ozanimod vs. interferon beta-1a in relapsing multiple sclerosis (SUNBEAM):  A multicentre, randomised, minimum 12-month, phase 3 trial":


https://www.ncbi.nlm.nih.gov/pubmed/31492651








Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
131 Views 		Last post September 30, 2018, 07:31:15 pm
by agate
0 Replies
62 Views 		Last post December 14, 2019, 04:59:16 pm
by agate
0 Replies
34 Views 		Last post December 02, 2020, 03:35:02 pm
by agate
0 Replies
37 Views 		Last post December 02, 2020, 03:37:34 pm
by agate
0 Replies
59 Views 		Last post May 11, 2021, 09:13:10 pm
by agate